Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content
The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain. In Alzheimer's disease (AD), the role of type 1 cannabinoid receptor (CB 1 R) is unclear, with contradictory... more
The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain. In Alzheimer's disease (AD), the role of type 1 cannabinoid receptor (CB 1 R) is unclear, with contradictory findings in post-mortem studies showing upregulation, down-regulation or unchanged CB 1 R status. We have investigated CB 1 R availability in vivo in patients with AD, in relation to amyloid deposition, cognitive functioning and apolipoprotein E (ApoE) genotype. Eleven AD patients and 7 healthy volunteers (HV) underwent combined [ 18 F]MK-9470 PET and [ 11 C]PIB PET scans to assess CB 1 R availability and amyloid deposition, respectively, and T1 volumetric MRI for partial volume correction. We found no difference in CB 1 R availability between AD and HV, VOI-based fractional uptake values (FUR) were 0.04370.01 for AD and 0.04570.01 for controls (p=0.9). CB 1 R availability did not correlate with neuropsychological test scores and was not modulated by ApoE genotype. As expected, global [ 11 C]PIB SUVR (standardized uptake value ratio) was increased in AD (SUVR 1.970.3) compared to HV (1.270.1) with po0.001, but no correlation was found between amyloid β (Aβ) deposition and CB 1 R availability. In conclusion, we found no in vivo evidence for a difference in CB 1 R availability in AD compared to age-matched controls. Taken together with recently reported in vivo CB 1 R changes in Parkinson's and Huntington's disease, these data suggest that the CB 1 R is differentially involved in neurodegenerative disorders.
PURPOSE: Chronic fatigue syndrome is a clinical entity consisting of prolonged and debilitating fatigue in which concentration disturbances are very frequent. Until now, no medical treatment has shown any efficacy. The objectives of this... more
PURPOSE: Chronic fatigue syndrome is a clinical entity consisting of prolonged and debilitating fatigue in which concentration disturbances are very frequent. Until now, no medical treatment has shown any efficacy. The objectives of this study were to investigate the short-term effects of methylphenidate, an amphetamine derivative, on fatigue, concentration disturbances, and quality of life. SUBJECTS AND METHODS: A double-blind randomized
The APA published the DSM-5 in May, 2013. When compared to dsm-iv, the latest edition incorporates many changes, some relating to neurocognitive disorders. To review critically the new DSM-5 alterations and adjustments relating to... more
The APA published the DSM-5 in May, 2013. When compared to dsm-iv, the latest edition incorporates many changes, some relating to neurocognitive disorders. To review critically the new DSM-5 alterations and adjustments relating to neurocognitive disorders. We compared the relevant chapters in DSM-IV-TR and DSM-5 and we searched the literature for articles involving discussions about cognitive disorders in DSM-5. With regard to differential diagnosis of neurocognitive disorders, DSM-5 has more in common with current clinical practice than does the DSM-IV. DSM-5 names ten etiological subtypes for which the diagnostic criteria are based on recent scientific research. However, some researchers and clinicians have reservations about using the term 'major neurocognitive disorder' instead of 'dementia', and are reluctant to make a distinction between 'mild' and 'major' cognitive disorders. The alterations and adjustments that appear in DSM-5 in relation to n...
To assess presence and severity of associative stigma in family members of psychotic patients and factors for higher associative stigma. Standardized semi-structured interview of 150 family members of psychotic patients receiving full... more
To assess presence and severity of associative stigma in family members of psychotic patients and factors for higher associative stigma. Standardized semi-structured interview of 150 family members of psychotic patients receiving full time treatment. This study on associative stigma in family members of psychotic patients was part of a larger research program on the burden of the family, using "Interview for the Burden of the Family" and the chapters stigma, treatment and attribution from the "Family interview Schedule". The respondents were relatives, one per patient, either partner or parent. The patients had been diagnosed with schizophrenia or schizo-affective disorder. All contacts with patients and relatives were in Dutch. Relatives were deemed suitable to participate in this research if they saw the patient at least once a week. Recruitment took place in a standardized way: after obtaining the patient's consent, the relatives were approached to partici...
Gastroenterology, Volume 124, Issue 4, Pages A215, April 2003, Authors:Philippe Persoons;Joris Vandenberghe; Koen Demyttenaere; Paul Rutgeerts. ... Philippe Persoons ,; JorisVandenberghe ,; Koen Demyttenaere ,; Paul Rutgeerts. Abstract;... more
Gastroenterology, Volume 124, Issue 4, Pages A215, April 2003, Authors:Philippe Persoons;Joris Vandenberghe; Koen Demyttenaere; Paul Rutgeerts. ... Philippe Persoons ,; JorisVandenberghe ,; Koen Demyttenaere ,; Paul Rutgeerts. Abstract; PDF. No full text is available. ...
Gastroenterology, Volume 124, Issue 4, Pages A211, April 2003, Authors:Philippe Persoons;Joris Vandenberghe; Koen Demyttenaere; Paul Rutgeerts. ... Philippe Persoons ,; JorisVandenberghe ,; Koen Demyttenaere ,; Paul Rutgeerts. Abstract;... more
Gastroenterology, Volume 124, Issue 4, Pages A211, April 2003, Authors:Philippe Persoons;Joris Vandenberghe; Koen Demyttenaere; Paul Rutgeerts. ... Philippe Persoons ,; JorisVandenberghe ,; Koen Demyttenaere ,; Paul Rutgeerts. Abstract; PDF. No full text is available. ...